Hero

News & Events

Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within

Fierce Biotech: Merck & Co. signs $1.9B deal with Mestag to explore fibroblast therapies for inflammation

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors

October 20, 2026

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting

Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic

Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia

View All Press Releases

Optimum’s 18th Healthcare Investor Conference – London, UK

October 8, 2026

Conference Website

ESMO Congress – Madrid, Spain

October 23-27, 2026

Conference Website

Jefferies Global Healthcare Conference in London – London, UK

November 16-19, 2026

Conference Website

SITC – Phoenix, US

November 4-8, 2026

Conference Website

45th Annual J.P. Morgan Healthcare Conference – San Francisco, US

January 11-14, 2027

Conference Website